ProShares Ultra NASDAQ Biotechnology
22 hedge funds and large institutions have $19.2M invested in ProShares Ultra NASDAQ Biotechnology in 2014 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
23% more capital invested
Capital invested by funds: $15.6M → $19.2M (+$3.57M)
10% more funds holding
Funds holding: 20 → 22 (+2)
49% less call options, than puts
Call options by funds: $8.88M | Put options by funds: $17.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.98M |
| 2 |
PCM
Prelude Capital Management
New York
|
+$1.32M |
| 3 |
AP
Advisors Preferred
Rockville,
Maryland
|
+$1.19M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$704K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$632K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$2.4M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$933K |
| 3 |
AIG
American International Group
New York
|
-$883K |
| 4 |
LPL Financial
San Diego,
California
|
-$720K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$615K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Millennium Management
New York
| – | -$469K | -11,740 | Closed |
|
|
S
27
SignatureFD
Atlanta,
Georgia
| – | -$14K | -340 | Closed |
|
BIB Hedge Fund Activity: Q2 2014 in Review
22 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2014, worth a combined $19.2M — up 23% from $15.6M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BIB positions and 5 closed out — a net gain of 2 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $1.98M. The largest seller was Zurich Cantonal Bank, exiting entirely with an estimated $2.4M sold.
- 22 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2014, up from 20 in Q1 2014.
- Funds reported $19.2M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2014, up 23% quarter-over-quarter.
- 7 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2014 and 5 closed out, a net change of +2 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2014 was Tower Research Capital (TRC), an estimated $1.98M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2014 was Zurich Cantonal Bank, an estimated $2.4M sold.
Based on aggregated 13F filings for Q2 2014.